Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chrdl1
- Development stage
- Preclinical
- Lead developer
- Forcefield Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Gene Therapies
- Administration
- Intravenous, Intramyocardial, Intraperitoneal, Intraarterial, Oral
01
Overview
Chrdl1 is a preclinical-stage cardioprotective therapeutic being developed by Forcefield Therapeutics for the treatment of acute myocardial infarction and the prevention of heart failure. Identified through the FunSel screening platform in collaboration with King's College London, Chrdl1 is one of several secreted proteins found to protect cardiomyocytes from death following a heart attack. Its mechanism of action involves the activation of autophagy, prevention of cardiomyocyte apoptosis, and inhibition of cardiac fibrosis through the suppression of TGF-beta signaling. The program is being developed using two distinct modalities: a recombinant protein therapeutic for acute administration and an AAV-based gene therapy for sustained effect, the latter of which is being developed in partnership with Freeline Therapeutics.
- Other names
- Chordin-like 1Chordin-like1Chordin-like-1
02
Targets
BMP4 (Bone morphogenetic protein 2)
Beyond the preview
Go deeper on Chrdl1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chrdl1.